BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC

Reuters

Dec 31, 2025

BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC

BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2595019776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595019776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595019776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595019776","market":"fut","top_or_hot":-1,"title":"BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-31 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL3Mn76f:1","article_id":"2595019776","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595019776","pubTimestamp":1767182417,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin  into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma . Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","BCAB":"BioAtla, Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"BioAtla与Inversagen AI合作推进Oz-V Senolytic疗法治疗OPSCC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAB":0.9,"NDAQ":0.9},"content_text":"BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC\n    \n\n        BioAtla Inc. has announced a partnership with Inversagen AI, LLC to advance Ozuriftamab Vedotin (Oz-V) into Phase 3 development for the treatment of patients with oropharyngeal squamous cell carcinoma (OPSCC). Inversagen AI, LLC—a new company formed by GATC Health Corp. and Inversagen LLC—will provide an initial $5 million for operating and clinical trial expenses, with an additional $35 million expected when the registrational clinical study begins in early 2026. Under the agreement, Inversagen AI will receive a 35% ownership stake in Oz-V, while BioAtla retains 65%. The collaboration aims to develop novel senolytic therapies targeting age-related diseases, with BioAtla maintaining rights to cancer therapeutic applications.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618495) on December 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}